HDAC6-IN-12
HDAC6-IN-12 (compound GZ) is a potent HDAC6 inhibitor. HDAC6-IN-12 has anticancer activity through merges into DNA strands causing DNA damage. HDAC6-IN-12 can be used for cancer research.
For research use only. We do not sell to patients.
- CAS No.: 2803866-44-4
- Formula: C24H39F2N3O5
- Molecular Weight:487.58
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| 4T1 | IC50 |
0.66 μM
Compound: GZ
|
Antiproliferative activity against mouse 4T1 cells assessed as inhibition of cell growth
Antiproliferative activity against mouse 4T1 cells assessed as inhibition of cell growth
|
[PMID: 35810950] |
| A549 | IC50 |
0.14 μM
Compound: GZ
|
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth
|
[PMID: 35810950] |
| HCT-116 | IC50 |
0.3 μM
Compound: GZ
|
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth
|
[PMID: 35810950] |
| HeLa | IC50 |
0.43 μM
Compound: GZ
|
Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth
Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth
|
[PMID: 35810950] |
| Huh-7 | IC50 |
0.12 μM
Compound: GZ
|
Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell growth
Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell growth
|
[PMID: 35810950] |
| MDA-MB-231 | IC50 |
0.072 μM
Compound: GZ
|
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated in presence of 10 uM imatinib
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated in presence of 10 uM imatinib
|
[PMID: 35810950] |
| MDA-MB-231 | IC50 |
0.14 μM
Compound: GZ
|
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth
|
[PMID: 35810950] |
| MDA-MB-231 | IC50 |
0.17 μM
Compound: GZ
|
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth pretreated with hENT1 inhibitor, dipyridamole at 10 uM followed by compound addition
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth pretreated with hENT1 inhibitor, dipyridamole at 10 uM followed by compound addition
|
[PMID: 35810950] |
| PANC-1 | IC50 |
1.08 μM
Compound: GZ
|
Antiproliferative activity against human PANC-1 cells assessed as inhibition of cell growth
Antiproliferative activity against human PANC-1 cells assessed as inhibition of cell growth
|
[PMID: 35810950] |
| SGC-7901 | IC50 |
3.7 μM
Compound: GZ
|
Antiproliferative activity against human SGC-7901 cells assessed as inhibition of cell growth
Antiproliferative activity against human SGC-7901 cells assessed as inhibition of cell growth
|
[PMID: 35810950] |
| SK-OV-3 | IC50 |
0.62 μM
Compound: GZ
|
Antiproliferative activity against human SK-OV-3 cells assessed as inhibition of cell growth
Antiproliferative activity against human SK-OV-3 cells assessed as inhibition of cell growth
|
[PMID: 35810950] |
In Vitro
HDAC6-IN-12 (compound GZ) (72 h) has anti-proliferative activity on tumor cells against HuH-7, HeLa, MDA-MB-231, SKOV3, A549, PANC-1, HCT-116, SGC7901 and 4T1 cells with IC50 values of 0.12 μM, 0.43 μM, 0.14 μM, 0.62 μM, 0.14 μM, 1.08 μM, 0.30 μM, 3.70 μM and 0.66 μM, respectively[1].
HDAC6-IN-12 (compound GZ) (0-3 μM; 24 h; MBA-MB-231 cells) merges into DNA strands causing DNA damage and increases the level of phospho-γ-H2A.X, which is the marker of DNA strand break[1].
HDAC6-IN-12 (compound GZ) (0-100 μM; 30 min) has major metabolic enzymes including CYP3A2, CYP1A1/2 isoforms[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MBA-MB-231 cells
-
Concentration:0, 0.1, 0.3, 1 and 3 μM
-
Incubation Time:24 hours
-
Result:Increased the level of phospho-γ-H2A.X in a dose-dependent manner.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Bablc female mice[1]
-
Dosage:5 and 10 mg/kg
-
Administration:Intraperitoneal injection; once every three days, for 15 days
-
Result:Inhibited tumor growth with TGI of 73.2% at 5 mg/kg and 83.8% at 10 mg/kg, respectively.
Chemical Information
-
CAS No. 2803866-44-4
-
Molecular Weight 487.58
-
Formula C24H39F2N3O5
-
SMILES
CCCCCCCCCCCCCCC(NC(C=CN1[C@@H]2O[C@H](CO)[C@H](C2(F)F)O)=NC1=O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Genotoxicity/Mutagenicity Study
The bacterial reverse mutation assay detects point mutations that restore amino-acid prototrophy in auxotrophic Salmonella typhimurium or Escherichia coli tester strains; after exposure to a test article, mutagenic activity is read out as an increased number of revertant colonies on minimal agar compared with the vehicle control. The assay uses tester strains with different mutation targets so that base-substitution and frameshift mutagens can be detected, and testing is performed with and without exogenous mammalian metabolic activation because some chemicals require biotransformation to become mutagenic.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)